Interactions between Atorvastatin and the Farnesoid X Receptor Impair Insulinotropic Effects of Bile Acids and Modulate Diabetogenic Risk

Theresa Hoffmeister, Julia Kaiser, Simon Lüdtke, Gisela Drews, and Martina Düfer

Institute of Pharmaceutical and Medicinal Chemistry, Department of Pharmacology, Münster, Germany (T.H., S.L., M.D.) and Institute of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Tübingen, Germany (J.K., G.D.)

Received August 8, 2019; accepted December 18, 2019

ABSTRACT

Bile acids such as chenodeoxycholic acid (CDC) acutely enhance insulin secretion via the farnesoid X receptor (FXR). Statins, which are frequently prescribed for patients with type 2 diabetes who suffer from dyslipidemia, are known for their diabetogenic risk and are reported to interact with the FXR. Our study investigates whether this interaction is relevant for beta cell signaling and plays a role for negative effects of statins on glycemic control. Experiments were performed with islets and islet cells from C57BL/6N wild-type and FXR-knockout (KO) mice. Culturing islets with atorvastatin (15 μM) for 24 hours decreased glucose-stimulated insulin secretion by approximately 30% without affecting ATP synthesis. Prolonged exposure for 7 days lowered the concentration necessary for impairment of insulin release to 150 nM. After 24-hour culture with atorvastatin, the ability of CDC (500 nM) to elevate [Ca²⁺]e was diminished and the potentiating effect on insulin secretion was completely lost. Mevalonate largely reduced the negative effect of atorvastatin. Nuclear activity of FXR was reduced by atorvastatin in a mouse FXR reporter assay. The atorvastatin-induced decrease in insulin release was also present in FXR-KO mice. Although not a prerequisite, FXR seems to influence the degree of damage caused by atorvastatin depending on its interaction with CDC. Preparations responding to CDC with an increase in insulin secretion under control conditions were less impaired by atorvastatin than preparations that were nonresponsive to CDC. Extended stimulation of FXR by the synthetic agonist GW4064, which is suggested to induce translocation of FXR from the cytosol into the nucleus, increased the inhibitory effect of atorvastatin. In conclusion, atorvastatin inhibits insulin release and prevents positive effects of bile acids on beta cell function. Both interactions may contribute to progression of type 2 diabetes mellitus.

SIGNIFICANCE STATEMENT

This study shows that the diabetogenic risk of statins is coupled to the activity of farnesoid X receptor (FXR)-dependent signaling pathways in beta cells. On the one hand, statins abolish the insulinotropic effects of bile acids and on the other hand, FXR determines the level of impairment of islet function by the statin.

Introduction

Statins prescribed to lower low-density lipoprotein (LDL) cholesterol are in broad clinical use. Their beneficial effects concerning prevention of cardiovascular risk are undisputed (Scandinavian Simvastatin Survival Study study group, 1994; Sever et al., 2003); nevertheless, certain side effects have to be considered (Thompson et al., 2016). A meta-analysis of 13 statin trials with 91,140 participants provides clear evidence that the risk to develop type 2 diabetes mellitus increases in patients during long-term statin therapy (Sattar et al., 2010).

Particularly, lipophilic statins such as atorvastatin are assumed to influence islet function in a detrimental way (Yada et al., 1999; Yaluri et al., 2015; Urbano et al., 2017). Whether this is associated with the hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibition or results from off-target effects, remains controversial. Partly the effects are closely linked to the mode of action of statins (Urbano et al., 2017), partly the observed effects are not reversible by a co-culture with mevalonate (Yaluri et al., 2015). Interestingly, it was shown that statins interact with pathways regulated by the farnesoid X receptor (FXR). Fu et al. (2014) reported effects of atorvastatin on FXR-induced target genes in mice, whereas Habeos et al. (2005) observed changes in the expression and DNA-binding activity of the receptor in the liver after treatment of Syrian hamsters with simvastatin as well as in simvastatin-treated HepG2 cells.

The FXR is a nuclear receptor targeted by bile acids like chenodeoxycholic acid (CDC), which is the most effective one (Makishima et al., 1999; Parks et al., 1999). It plays a role for regulation of lipid and bile acid metabolism and also for glucose homeostasis (Fiorucci et al., 2009; Dürer et al., 2012a). FXR expression is high in liver, adrenal glands, and intestine (Huber et al., 2002); however, mRNA can also be found in other organs like the endocrine pancreas (Popescu et al., 2010). In our previous work, we investigated the impact of an acute stimulation of the FXR by the bile acid taurochenodeoxycholic

ABBREVIATIONS: AUC, area under the curve; CDC, chenodeoxycholic acid; FXR, farnesoid X receptor; HMG-CoA, hydroxy-methyl-glutaryl coenzyme A; KO, knockout; PXR, pregnane X receptor.
acid on insulin secretion. We detected an FXR-dependent insulinotrophic effect of the bile acid, which includes inhibition of KATP channels, membrane depolarization and increased Ca\(^{2+}\) influx (Düfer et al., 2012b). For this acute stimulatory effect on insulin secretion, cytosolic localization of FXR, and bile acid–induced interaction with KATP channels are essential.

The reported impact of statins on FXR in liver and intestine, respectively (Habeo et al., 2005; Fu et al., 2014), raises the question of a comparable situation in the pancreas. The aim of our study was to gain insight into possible interactions between FXR and statins in pancreatic islets. Therefore, the influence of atorvastatin and its interaction with bile acid signaling was investigated in islets of wild-type and FXR-knockout (KO) mice by monitoring membrane potential, cytosolic Ca\(^{2+}\) concentration ([Ca\(^{2+}\)]\(_i\)), ATP, apoptosis, and insulin release and content. In addition, a reporter assay was used to test for interactions of statins with transcriptional activity of FXR.

**Materials and Methods**

**Cell and Islet Preparation.** Experiments were performed with islets of Langerhans from adult male and female C57BL/6N mice (Charles River, Sulzfeld, Germany) or adult male and female FXR-deficient mice (age of 9 ± 3 months) from a C57BL/6N background described earlier (Sinal et al., 2000). The principles of laboratory animal care were followed according to German laws (Az. 53.5.32.7.1/MS-12668, health and veterinary office Münster, Germany). Mice were euthanized by CO\(_2\). Islets were isolated by collagenase digestion. Dispersed cells or smaller cell clusters were obtained by trypsinization and used for membrane potential and [Ca\(^{2+}\)]\(_i\) measurements and for determination of apoptosis. Islets and cells were cultured in RPMI 1640 medium (11.1 mM glucose) supplemented with 10% fetal calf serum, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C in 5% CO\(_2\) humidified atmosphere. After preparation, islets or dispersed islet cells were kept overnight in standard culture medium. The next day, incubation started in the presence of atorvastatin or pravastatin for 24 hours or 7 days. In case of preincubations with GW4064 atorvastatin was added 1 day later. Medium was changed every 2nd or 3rd day during the long-term incubation of 7 days.

**Solution and Chemicals.** Insulin secretion was performed in bath solution containing [millimolars]: 122 NaCl, 4.7 KCl, 1.1 MgCl\(_2\), 2.5 CaCl\(_2\), 10 HEPES (pH 7.4) and 0.5% bovine serum albumin. [Ca\(^{2+}\)]\(_i\), membrane potential and ATP were measured in a solution that contained [millimolars]: 140 NaCl, 5 KCl, 1.2 MgCl\(_2\), 2.5 CaCl\(_2\), 10 HEPES (pH 7.4). Pipette solution for electrophysiology contained [millimolars]: 10 KCl, 10 NaCl, 70 K\(_2\)SO\(_4\), 4 MgCl\(_2\), 2 CaCl\(_2\), 10 EGTA, 20 HEPES, 250 µM amphotericin B, pH 7.15. Glucose was added as indicated.

Collagenase P was from Roche Diagnostics (Mannheim, Germany); annexin V reagent was from Essen BioScience (Michigan); RPMI 1640, fetal calf serum, and penicillin/streptomycin were obtained from Life Technologies (Darmstadt, Germany). The statins used were: atorvastatin [IUPAC name: (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-1640, fetal calf serum, and penicillin/streptomycin were obtained from Annexin V reagent was from Essen BioScience (Michigan); RPMI indicated.

**Intracellular Calcium.** Intracellular calcium was measured with fura-2 AM (5 mM, Sigma-Aldrich or Diagonal (Münster, Germany), primary and secondary antibodies were from Merck Millipore (Rat Insulin RIA, RI-13K) provided by Biotrend. All other chemicals were from Sigma–Aldrich or Diagonal (Münster, Germany). Fura-2 AM was ordered from Biotrend (Köln, Germany). Labeled \(^{125}\)I-insulin was kindly provided by Sanofi (Frankfurt, Germany), primary and secondary antibodies were from Merck Millipore (Rat Insulin RIA, RI-13K) provided by Biotrend. All other chemicals were from Sigma–Aldrich or Diagonal (Münster, Germany).

**Intracellular Calcium.** Intracellular calcium was measured with fura-2 AM (5 mM, Sigma-Aldrich or Diagonal (Münster, Germany), primary and secondary antibodies were from Merck Millipore (Rat Insulin RIA, RI-13K) provided by Biotrend. All other chemicals were from Sigma–Aldrich or Diagonal (Münster, Germany). Fura-2 AM was ordered from Biotrend (Köln, Germany). Labeled \(^{125}\)I-insulin was kindly provided by Sanofi (Frankfurt, Germany), primary and secondary antibodies were from Merck Millipore (Rat Insulin RIA, RI-13K) provided by Biotrend. All other chemicals were from Sigma–Aldrich or Diagonal (Münster, Germany).
area in relation to the whole cell area was determined. Membrane potential was analyzed by averaging the values of the last 30 seconds before changes in bath solution. Values are presented as mean ± S.D. To compare two single groups, Student’s t test was performed. For comparison among groups, statistical significance was assessed by ANOVA followed by Student-Newman-Keuls post hoc test. The null hypothesis of each series of experiments was that the test compound has no influence on the respective parameter. Values of $P < 0.05$ were considered statistically significant.

**Results**

**Atorvastatin Decreases Glucose-Stimulated Insulin Secretion.** To investigate the effect of atorvastatin on insulin secretion, two incubation periods with different concentrations of the HMG-CoA reductase inhibitor were chosen.

Culturing islets in the presence of 15 μM atorvastatin for 24 hours significantly decreased insulin release stimulated by 15 mM glucose. Islets exposed to 1.5 μM atorvastatin for 24 hours only showed a tendency to reduced insulin secretion in response to stimulation with 15 mM glucose (Fig. 1A). The culture period in medium supplemented with various concentrations of atorvastatin was extended to 7 days to investigate the influence of time. This prolonged treatment potentiated the detrimental effect of 15 μM atorvastatin on glucose-stimulated insulin secretion [24 hour: 3.3 ± 0.9 ng/islet*h], n = 10, vs. 7 days: 1.3 ± 0.9 ng/islet*h], n = 13, $P < 0.001$. Moreover, already nanomolar concentrations of the statin (150 and 500 nM) showed a negative effect on insulin release after 7 days (Fig. 1B). Because extension of the time period to 7 days led to stronger variations in secretion among the individual preparations, absolute values were calculated as percentage of control (15 mM glucose) in this series of experiments. To investigate whether the reduction of insulin release by atorvastatin is related to inhibition of HMG-CoA reductase, mevalonate (500 μM) was added to the culture medium. Mevalonate completely prevented the effect of atorvastatin regarding the 24-hour culture period (Fig. 1C) and partly protected the islets during the extended treatment of 7 days (Fig. 1D).

**Atorvastatin Changes Cytosolic Ca$^{2+}$ but Has No Effect on Cell Viability or ATP Synthesis.** Because the rise in [Ca$^{2+}$]c is crucial for insulin secretion, it was tested whether the inhibitory effect of atorvastatin is caused by changes in [Ca$^{2+}$]c. Incubating islet cells with 15 μM atorvastatin for 24 hours slightly altered the Ca$^{2+}$ response to a glucose stimulus: After exposure to atorvastatin, the first increase in [Ca$^{2+}$]c in response to 15 mM glucose was approximately half a minute delayed compared with standard conditions (Fig. 2A). Apart from the effect on response time, pretreatment with atorvastatin reduced the mean concentration of [Ca$^{2+}$]c (Fig. 2B).

Insulin content was not affected even after incubating pancreatic islets in standard culture medium (10 mM glucose) supplemented with atorvastatin for the long-term period of 7 days (Fig. 2C). Corresponding to these results, there was no induction of apoptosis by the exposure of islet cells to 15 μM atorvastatin in standard culture medium for up to 44 hours compared with the control (% apoptotic area after 24 hours: control 8.0% ± 1.5% vs. 15 μM atorvastatin, 24 hours, 8.9% ± 2.6%, n = 3, not significant) (Fig. 2D). As atorvastatin was reported to depolarize mitochondria isolated from rat pancreata and to reduce ATP content of the insulin-secreting cell line INS1 (Sadighara et al., 2017; Urbano et al., 2017), we tested whether atorvastatin affects glucose-stimulated ATP generation in murine islets. ATP content of islets stimulated with 0.5 or 15 mM glucose after 24-hour culture with
atorvastatin (15 μM) was not different compared with controls (Fig. 2E), excluding severe impairment of mitochondrial function by the drug.

**Atorvastatin Abolishes the Insulinotropic Effect of the Bile Acid CDC.** To evaluate if atorvastatin influences the FXR or its signaling pathway in pancreatic islets as described for the liver (Fu et al., 2014), the acute effect of the bile acid CDC on insulin secretion was tested after culturing islets under control conditions or in the presence of 15 μM atorvastatin for 24 hours. Additionally, 200 μM pravastatin were tested under the same conditions.

The acute application of CDC in a concentration of 500 nM enhanced insulin secretion under standard conditions as described earlier (Düfer et al., 2012b). Interestingly, culturing islets with 15 μM atorvastatin for 24 hours abolished the acute insulinotropic effect of CDC (Fig. 3A). In this series of experiments, CDC elevated insulin secretion from 3.6 ± 1.2 to 4.7 ± 1.7 ng/(islet*h), n = 13, P ≤ 0.05. After culture with 15 μM atorvastatin for 24 hours, glucose-stimulated insulin release (1 hour) was 2.7 ± 1.2 ng/(islet*h) in the absence and 2.5 ± 1.1 ng/(islet*h) in the presence of CDC (500 nM) (n = 13, not significant). This was also fact for the lower concentration of 1.5 μM atorvastatin (insulin release in response to 15 mM glucose after 24-hour culture with 1.5 μM atorvastatin: 4.1 ± 2.3 ng/(islet*h) vs. same conditions + CDC 500 nM: 4.6 ± 3.4 ng/(islet*h), n = 6, not significant).

The same experiment was performed with pravastatin, which is more hydrophilic than atorvastatin. Twenty-four-hour culture with 200 μM pravastatin also inhibited the stimulatory effect of CDC (Fig. 3B), pointing to a class effect of statins [insulin release in response to 15 mM glucose after 24-hour culture with pravastatin: 3.6 ± 1.5 ng/(islet*h) vs. same conditions + CDC 500 nM: 3.1 ± 1.4 ng/(islet*h), n = 12, not significant].

Because the effect of CDC on insulin secretion depends on a rise in [Ca^{2+}], this parameter was measured in islet cells and cell clusters that were exposed to 15 μM atorvastatin prior to the experiment for 24 hours. [Ca^{2+}], was determined by calculating the AUC after baseline correction. In agreement with the acute effect on insulin secretion described above, the acute application of 500 nM CDC provoked an increase in [Ca^{2+}] under control conditions. This was significantly diminished after exposure of the cells to atorvastatin (Fig. 3C), explaining the ineffectiveness of CDC on insulin secretion...
after treatment with the lipophilic statin. Because the effect of bile acids on [Ca^{2+}]_{c} is regulated by electrical activity, a drug eliminating the CDC-induced changes in [Ca^{2+}]_{c} is expected to interact with the influence of CDC on membrane potential. To verify this hypothesis, membrane potential of beta cells was determined in the perforated-patch configuration. These experiments were started in the presence of 5.5 mM glucose, i.e., a concentration in the range of the threshold for induction of Ca^{2+} action potentials. CDC was added at a concentration of 500 nM for approximately 7 minutes. If the seal was stable enough, glucose was elevated to 15 mM (CDC still present) at the end of the experiment to verify metabolic integrity. Application of CDC depolarized the membrane in control cells but did not induce any change in cells pretreated with 15 \textmu M atorvastatin for 24 hours (Fig. 3D). Of note, most of the atorvastatin-pretreated cells appeared to be more depolarized.
at 5.5 mM glucose compared with the control cells. The lack of effect of CDC after application of the statin supports the idea that these drugs disrupt the coupling of the CDC/FXR-pathway and electrical activity, thereby reducing the effect of CDC on Ca\(^{2+}\) influx.

**Atorvastatin Interacts with FXR-Response Elements.** To test whether atorvastatin influences the activity of FXR, a mouse luciferase reporter assay was used. Genetically manipulated cells, where expression of luciferase is controlled by an FXR-responsive promotor, were cultured either with 15 \(\mu M\) atorvastatin alone or in combination with 1 \(\mu M\) of the synthetic FXR activator GW4064 for 24 hours and luciferase-catalyzed changes in bioluminescence were monitored thereafter. Although atorvastatin did not influence FXR activity per se, GW4064-induced activation was dose-dependently diminished (Fig. 4, A and B). Interestingly, additional treatment with mevalonate (500 \(\mu M\)) during culture partly protected against the inhibition of FXR by atorvastatin (Fig. 4C).

Because 10 \(\mu M\) atorvastatin were reported to activate the CYP-regulating nuclear pregnane X receptor (PXR) (Howe et al., 2011), we also checked whether activation of this receptor might mimic the negative influence of atorvastatin on insulin release. Therefore, the PXR agonist pregnenolone-16alpha-carbonitrile was used. 10 or 25 \(\mu M\) of this compound only showed a slight, nonsignificant tendency to reduced glucose-stimulated insulin release (Fig. 4D) and did not mirror the effect of atorvastatin.

**Inhibitory Effect of Atorvastatin in FXR-Deficient Islets.** We demonstrated in previous work that the increase in [Ca\(^{2+}\)]\(_i\) in response to bile acids depends on FXR and is absent in beta cells of FXR-KO mice (Düfer et al., 2012b). Consequently, the results described above indicate an interaction between statins and the FXR, leading to elimination of the insulinotropic effect of CDC. This interaction provoked the question whether there might also be an impact vice versa. Therefore, the experiments shown in Fig. 1A were repeated with pancreatic islets from FXR-deficient mice. After exposing FXR-KO islets to different concentrations of atorvastatin for 24 hours, 15 \(\mu M\) atorvastatin caused a significant decline in insulin secretion, while a concentration of 1.5 \(\mu M\)—similar to

---

**Fig. 4.** Nuclear activity of FXR is inhibited by atorvastatin but FXR is not essential for statin-mediated inhibition of insulin secretion. (A) Reporter cells expressing luciferase under control of the FXR were treated with increasing concentrations of atorvastatin or GW4064 for 24 hours. (B and C) To run the assay in the antagonist mode, reporter cells were incubated with 1 \(\mu M\) of the synthetic FXR agonist GW4064 for 24 hours. This was combined with different concentrations of atorvastatin without (B) or with (C) 500 \(\mu M\) mevalonate. Thereafter, substrate was added and luminescence was determined. Atorvastatin was without effect per se but inhibited the increase in luminescence induced by GW4064. This increase was partly outweighed by application of mevalonate. (D) Pregnenolone carbonitrile (10 and 25 \(\mu M\), 24 hours) did not affect glucose-stimulated (15 mM glucose, 1 hour) insulin secretion. (E) Culturing pancreatic islets of FXR-deficient mice for 24 hours in standard medium supplemented with atorvastatin (15 \(\mu M\)) decreased glucose-induced insulin secretion in a concentration-dependent manner similar to wild-type islets. The number of independent preparations is given below the bars of the diagram. Islets were isolated from female/male mice as follows: 2/4 (D), 4/4 (E). #P < 0.001 vs. all other conditions; *P < 0.05.
the effect in wild-type islets—only tended to reduce insulin release (Fig. 4E).

Comparison of the amounts of insulin, secreted in response to 15 mM glucose (1 hour, expressed as percentage of control) after 24-hour culture of the islets with 15 μM atorvastatin, revealed no difference between wild-type and FXR-deficient islets [insulin secretion after 24-hour culture with atorvastatin (15 μM): wild-type 64.7% ± 28.9% of control, n = 27, vs. FXR-KO 66.6% ± 29.6% of control, n = 8, not significant].

**FXR Modulates the Damaging Effect of Atorvastatin.** Although the experiments with FXR-deficient islets show the independency of the negative effect of atorvastatin on insulin secretion from the nuclear receptor per se, we made a remarkable observation after detailed analysis of the experiments with wild-type islets. Of 27 experiments with wild-type islets, not every preparation responded to the acute application of 500 nM CDC with an increase in insulin secretion under control conditions. Some preparations were nonresponsive to the bile acid, which means that the cytosolic K_{ATP}/Ca^{2+}-dependent signaling pathway of FXR is not operative. This might indicate a shift in the localization of FXR from the cytosol to the nucleus of the cell (Schittenhelm et al., 2015). To address this issue, the preparations were divided into two groups, CDC-responsive and CDC-nonresponsive experiments, for subgroup analysis. As a result, we detected a modulatory role of the FXR concerning the degree of damage caused by atorvastatin. Atorvastatin seems to be less harmful when islets are CDC responsive, whereas the inhibitory effect is aggravated when islets are nonresponsive to CDC under control conditions (Fig. 5A): After 24-hour treatment with 15 μM atorvastatin, glucose-stimulated insulin secretion was reduced to 77.0% ± 28.4% of control in CDC-responsive preparations (n = 17). By contrast, 24-hour treatment of CDC-nonresponsive preparations with atorvastatin lowered glucose-stimulated insulin release to 43.8% ± 14.3% of control (n = 10). It is noteworthy that we observed that the inhibitory effect of atorvastatin on insulin release of CDC-nonresponsive wild-type preparations was higher than in FXR-KO islets (Fig. 5B). This points to a more negative effect of statins when FXR is still present but lost its influence on the cytosolic pathway compared with complete absence of the receptor.

To confirm that FXR influences the damaging effect of atorvastatin, experiments were performed in which the FXR was forced into the nucleus of the cell. To achieve this, islet cells were exposed to the strong, synthetic FXR agonist GW4064 for an extended period. Previous work showed that the cytosolic, K_{ATP}-dependent signaling pathway of FXR is inactive after prolonged receptor activation by GW4064 (Schittenhelm et al., 2015). To be able to compare the degree of damage caused by atorvastatin as a function of the ability of FXR to act as a cytosolic receptor, only preparations responding to 500 nM CDC under control conditions, but not after 48-hour culture with GW4064, were included. Figure 5C shows that GW4064-treated islets, which have lost the cytosolic pathway of FXR (dark gray vs. light gray bar), were much more sensitive to the inhibitory influence of atorvastatin compared with control (black vs. white bar). As already described above, atorvastatin had only a small effect on islets of CDC-responsive preparations (~14% inhibition in this series of experiments). After preincubation of the islets with GW4064 (500 nM) for 24 hours and addition of the statin for another 24 hours, insulin secretion induced by 15 mM glucose was diminished by 80%. Of note, glucose-stimulated insulin release was approximately twofold higher after 48-hour culture with GW4064 compared with control.

Finally, the influence of HMG-CoA reductase on the interaction between atorvastatin and CDC/FXR was elucidated. Therefore, mevalonate (500 μM) was added to the culture medium in addition to atorvastatin. As expected, CDC did not stimulate insulin release after treatment with atorvastatin for 24 hours. However, stimulation of islets with 500 nM CDC was clearly improved in those islets where inhibition of endogenous mevalonate synthesis was compensated by external mevalonate supplementation (Fig. 5D).

**Discussion**

In accordance with other publications (Zhao and Zhao, 2015; Urbano et al., 2017), incubation of pancreatic islets with atorvastatin reduced insulin secretion. Noteworthy, experiments varied among species and concentration of atorvastatin. We tested atorvastatin in concentrations up to 15 μM. The high concentration, which exceeds circulating plasma levels in patients, was used to mimic accumulation of the lipophilic drug in vitro within a relatively short period of time because isolated beta cells are difficult to culture for several weeks. To test whether lower concentrations are also effective, we extended our protocol to 7 days. We observed that the effect of atorvastatin is not only dose dependent (Fig. 1A) but also time dependent: Besides the potentiation of the detrimental effect of 15 μM atorvastatin, a decrease in insulin release was already provoked by nanomolar concentrations (150 and 500 nM) of the statin after long-term treatment of 7 days (Fig. 1B). This concentration range is still approximately three- to fourfold higher than plasma concentrations reported in bioequivalence studies (e.g., http://www.mhra.gov.uk/home/groups/par/documents/websitesresources/con279868.pdf, UK/H/3430/004/DC), but one must keep in mind that in vitro the drug has to cross the barrier of connective tissue surrounding murine islets and is not distributed via systemic circulation.

The inhibitory effect of atorvastatin was not accompanied by a decrease in glucose-stimulated ATP synthesis but involves changes in Ca^{2+} influx (Fig. 2, A, B, and E), which points to an interaction with the triggering pathway that regulates beta cell function. Even though the exact mechanism remains to be elucidated, the diabetogenic effect of atorvastatin is unquestioned. Insulin content was not altered between control or any of the applied concentrations of atorvastatin even after 7 days (Fig. 2C). However, glucose-stimulated insulin release could be fully restored when mevalonate was added to the islets during the 24-hour culture with atorvastatin. This suggests that downstream metabolites of the cholesterol biosynthesis pathway are involved. The mevalonate rescue was only partial in the long-term experiments of 7 days, indicating that the deleterious effect of atorvastatin does not completely depend on inhibition of HMG-CoA reductase. Because some statins activate the xenobiotic receptor PXR (Howe et al., 2011), we tested whether the known PXR agonist pregnenolone carboxonitrile induces inhibitory effects similar to atorvastatin. The lack of any significant effect after 24-hour culture (Fig. 4D) argues against a major role of such an interaction in beta cells.

In contrast to reports of others (Zhao and Zhao, 2015; Sadighara et al., 2017), we could not attribute the detrimental effect on insulin secretion to changes in cell viability.
These discrepancies might result from different experimental approaches, as the effect of atorvastatin on cytochrome c release was monitored in isolated mitochondria (Sadighara et al., 2017) and cell survival was investigated by an assay testing the metabolic activity via reduction of dimethyl-thiazolyl-tetrazolium salt (MTT assay), which does not give any information about apoptosis (Zhao and Zhao, 2015). In summary, an effect of atorvastatin on insulin biosynthesis or a dramatic loss of beta cell mass can be ruled out as explanations for the decrease in insulin release in our investigation.

Our data show for the first time that statins interfere with the insulinotropic effect of bile acids. In the postprandial state, plasma levels of bile acids can rise up to 15 μM (Everson, 1987; Houten et al., 2006). This is not only necessary for the absorption of lipids but also important for lowering blood sugar peaks by stimulation of insulin secretion. The stimulatory effect of the FXR-agonistic bile acid CDC, which we already described in our previous investigations (Düfer et al., 2012b; Schittenhelm et al., 2015), was clearly seen under control conditions but completely disappeared after 24-hour culture with atorvastatin or pravastatin (Fig. 3, A and B). Corresponding to this loss of efficacy on glucose-stimulated insulin release, the influence of CDC on membrane potential was impaired and the CDC-mediated increase in [Ca^{2+}]_i was reduced to less than 50% (Fig. 3, C and D). For patients being treated with statins, this implies not only a decline in islet function induced by the statin per se but also the loss of an important physiologic regulatory function of bile acids for glucose homeostasis. In addition, a reduction of the postprandial plasma concentrations of bile acids was reported in patients with obesity (Glicksman et al., 2010) and patients who are prediabetic (Shaham et al., 2008), actually patient groups with the common indication for cholesterol-lowering drugs such as statins. Taken together, the already reduced contribution of bile acids to the postprandial regulation of blood glucose concentration in those patients would be progressively more or, worst case, entirely abolished during long-term therapy with statins. The exact mechanism leading to inhibition of the effect of CDC needs to be further investigated. Because the link between FXR activation and K_{ATP} channel closure has not yet been clearly identified, it might be possible that incubation with atorvastatin interferes with some target downstream to FXR, but upstream to the closure of K_{ATP} channels. Bearing in mind that statins impair the prenylation and thereby regulation of proteins by inhibiting...
the mevalonate pathway (Li et al., 1993), atorvastatin could disrupt some factor derived from this pathway linking FXR stimulation to K\textsubscript{ATP} channel closure. In agreement with this assumption, coculture with mevalonate rescued the sensitivity of islets to acute stimulation with CDC (Fig. 5D). Furthermore, our results demonstrate that the interference between atorvastatin and the FXR is not unilateral but of a bidirectional character. The experiments with FXR-KO islets show that the impairing effect induced by atorvastatin is partly independent of FXR (Fig. 4E). But in addition, our data reveal that FXR plays a modulatory role with regard to the degree of damage caused by the statin (Fig. 5, A and B). The availability of the receptor in the cytosol seems to be crucial for this modulation. Apparently, a localization close to the plasma membrane that enables interaction of FXR with the cytosolic triggering pathway for insulin secretion via K\textsubscript{ATP} channel closure and Ca\textsuperscript{2+} influx is protective and reduces the negative effect of atorvastatin on insulin release. Disruption of this pathway is associated with an increased inhibitory effect of statins on insulin release (Fig. 5C).

Popescu et al. (2010) detected a translocation of the FXR into the nucleus in obese ob/ob mice, whereas the receptor is mainly located in the cytosol in wild-type beta cells. Howe et al. (2011) reported that atorvastatin was not able to activate the FXR. We confirmed this result in a mouse FXR reporter assay. Furthermore, we demonstrate for the first time that atorvastatin inhibits nuclear FXR activity (Fig. 4B). If this also applies to pancreatic beta cells, suppression of genes of fundamental differences in FXR function, dependent on receptor isoforms through the use of alternative promoters. Newer studies indicate that HMG-CoA reductase-dependent modifications of FXR are generally required for regular functions of the receptor with respect to both cytosolic and nuclear signaling. The nature of these alterations as well as the FXR-regulated target genes that are suppressed by atorvastatin have to be characterized in further studies.

With respect to the pathway described above, differences in receptor localization—and thereby in receptor function—between lean and obese organisms might be critical determinants for the statin-bile acid interaction. In line with the idea of fundamental differences in FXR function, dependent on body weight and/or lipid homeostasis, it was reported that ablation of FXR is associated with decreased insulin secretion and insulin content under control conditions as well as peripheral insulin resistance (Cariou et al., 2006; Popescu et al., 2010). However, these negative characteristics completely change in a glucolipotoxic environment. FXR-deficient islets were resistant to glucolipotoxicity, whereas wild-type islets kept in glucolipotoxic medium showed an impaired glucose-stimulated insulin release (Schittenhelm et al., 2015). Supporting the hypothesis that—in beta cells—cytosolic localization of FXR is a prerequisite for its positive impact on cellular function, Schittenhelm et al. (2015) demonstrated that the potentiating effect of FXR agonists on insulin secretion is lost in islets derived from mice after high-fat diet. Taken together, these data suggest that certain conditions (i.e., genetic or diet-induced obesity in vivo, glucolipotoxicity or prolonged receptor activation in vitro) disrupt the cytosolic interaction between FXR and K\textsubscript{ATP} channels and might thereby aggravate the diabetogenic risk of statins. It is tempting to speculate that patients with obesity might be exceptionally sensitive to statin-induced beta cell damage as—similar to the genetic mouse model or to islets kept in a glucolipotoxic environment—their profile of FXR distribution and interaction may change during disease. Therefore, they not only lose the beneficial effect of bile acids on the endocrine pancreas but also risk progression of beta cell failure by direct statin-induced impairment of glucose-stimulated insulin release.

Acknowledgments
We thank Melanie Arning for excellent technical assistance.

Authorship Contributions

Participated in research design; Hoffmeister, Drews, Düfer.

Conducted experiments: Hoffmeister, Kaiser, Lüdtke.

Performed data analysis: Hoffmeister, Kaiser, Lüdtke, Düfer.

Wrote or contributed to the writing of the manuscript: Hoffmeister, Kaiser, Lüdtke, Drews, Düfer.

References


Address correspondence to: Dr. Martina Düfer, Pharmaceutical and Medicinal Chemistry, Dept. of Pharmacology, PharmaCampus, Corrensstraße 48, 48149 Münster, Germany. E-mail: martina.duefer@uni-muenster.de